← All trials
NCT04512105
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 2, 2020
- Primary completion
- Apr 20, 2022
- Completion date
- Jun 1, 2022
- First posted
- Aug 13, 2020
- Last posted
- Dec 4, 2020
- Enrollment
- 15
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of California, IrvineLead sponsor
- Department of DefenseCollaborator
- University of California, IrvineReponsible party - principal investigator
- Chao Family Comprehensive Cancer CenterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.